Render Target: STATIC
Render Timestamp: 2024-11-05T09:39:33.776Z
Commit: 57f6e368eba1a427377652f2ad915d45d7f340a4
XML generation date: 2024-09-30 01:57:57.811
Product last modified at: 2024-09-30T15:00:08.809Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ATAD2 (E8Y7F) Rabbit mAb #50563

Filter:
  • WB
  • IP
  • IHC
  • IF

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 180
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:50 - 1:200
    Immunofluorescence (Frozen) 1:400 - 1:1600
    Immunofluorescence (Immunocytochemistry) 1:400 - 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ATAD2 (E8Y7F) Rabbit mAb recognizes endogenous levels of total ATAD2 protein. Presumed non-specific punctate staining has been observed by immunofluorescence in a population of cells in fixed-frozen mouse testis tissue.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human ATAD2 protein.

    Background

    ATPase family AAA domain containing protein 2 (ATAD2) is an oncogenic protein that was originally identified as a coactivator for estrogen receptor (ESR1), and later identified as a coactivator for other transcription factors including c-Myc and E2F1, E2F2, and E2F3 proteins (1-4). ATAD2 is highly expressed and associated with poor prognosis in many types of cancer, including breast, uterine, colon, ovarian, stomach, non-small cell lung carcinoma, osteosarcoma, and cervical cancer (1,5-14). In cancer cells, overexpressed ATAD2 interacts with transcription factors and chromatin modifier proteins to induce the expression of genes that promote cell proliferation and inhibit apoptosis, ultimately promoting tumor growth (15,16). Indeed, knockdown of ATAD2 in pancreatic cancer cell lines has been shown to promote apoptosis, limit cell migration and invasion, and inhibit anchorage-independent growth (17). ATAD2 is a member of the ATPases associated with various cellular activities (AAA) family of proteins and contains a functional AAA domain in its central region, as well as a bromodomain near the C-terminus. The bromodomain binds to acetylated lysine residues on histone proteins, targeting ATAD2 protein to areas of active transcription, where it modulates chromatin structure and recruits additional transcription factors (18,19). Current efforts are underway to better characterize and develop inhibitors to the ATAD2 bromodomain for the treatment of various cancers (16,20-23).
    1. Zou, J.X. et al. (2007) Proc Natl Acad Sci U S A 104, 18067-72.
    2. Zou, J.X. et al. (2009) Cancer Res 69, 3339-46.
    3. Revenko, A.S. et al. (2010) Mol Cell Biol 30, 5260-72.
    4. Ciró, M. et al. (2009) Cancer Res 69, 8491-8.
    5. Wang, Y. et al. Lancet 365, 671-9.
    6. Teschendorff, A.E. et al. (2006) Genome Biol 7, R101.
    7. Fellenberg, J. et al. (2007) Mod Pathol 20, 1085-94.
    8. Petroziello, J. et al. (2004) Oncogene 23, 7734-45.
    9. De Angelis, P.M. et al. (2006) Mol Cancer 5, 20.
    10. Zheng, L. et al. (2015) Oncol Rep 33, 2337-44.
    11. Fouret, R. et al. (2012) Clin Cancer Res 18, 5606-16.
    12. Wan, W.N. et al. (2014) Asian Pac J Cancer Prev 15, 2777-83.
    13. Wu, G. et al. (2014) BMC Cancer 14, 107.
    14. Zhang, M. et al. (2016) Clin Transl Oncol 18, 776-81.
    15. Caron, C. et al. (2010) Oncogene 29, 5171-81.
    16. Boussouar, F. et al. (2013) Biochim Biophys Acta 1829, 1010-4.
    17. Liu, N. et al. (2019) Oncol Lett 17, 3489-94.
    18. Morozumi, Y. et al. (2016) J Mol Cell Biol 8, 349-62.
    19. Koo, S.J. et al. (2016) Oncotarget 7, 70323-35.
    20. Gay, J.C. et al. (2019) Proteins 87, 157-67.
    21. Hussain, M. et al. (2018) Expert Opin Ther Targets 22, 85-96.
    22. Bamborough, P. et al. (2018) J Med Chem 61, 8321-36.
    23. Zhou, Y. et al. (2018) Phys Chem Chem Phys 20, 23222-32.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Alexa Fluor is a registered trademark of Life Technologies Corporation.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.